Valeant Pharmaceutic
VRX
End-of-day quote Toronto Stock Exchange - 12/12
28.18CAD
+6.54%
Prev.26.4500
Open26.4400
High28.5400
Low26.2700
Volume5 991 798
Last news
Financials
Sales 2017 8 722 M
EBIT 2017 3 303 M
R. net 2017 156 M
Debt 2017 25 485 M
Rend. 2017 -
P/E ratio 2017 4,48
P/E ratio 2018
EV / Sales 2017 3,80x
EV / Sales 2018 3,67x
Capitalization 7 631 M
Company
Valeant Pharmaceuticals International, Inc. engages in the development, manufacture, and market of a broad range of pharmaceutical products in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics.It operates through the following segments: The Bausch +...
Sector :
Pharmaceuticals - NEC
Calendar :
2017-12-14 Presentation
Trading Rating :
Investor Rating :
Technical analysis trends
Short TermMid-TermLong Term
TrendBullishBullishBullish
Resistance31,231,229,3
Spread/Res.-9,6%-9,6%-3,8%
Spread/Supp.45%45%55%
Support19,519,518,1